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Natural killer (NK) cells kill tumor and virus-infected cells using activating NK cell receptors. One of the major
NK-activating receptors is NKp46 and its mouse ortholog Ncr1. NKp46/Ncr1 is expressed exclusively on NK cells and on a
subset of innate lymphoid cells. NKp46/Ncr1 was shown to be involved in a myriad of pathologies and immunological
settings. Speciﬁcally, NKp46/Ncr1 was shown to interact with the viral hemagglutinin (HA) protein and with an unknown
tumor/cellular ligand. NKp46 and Ncr1 are structurally similar; however, they are substantially different in their glyco-
sylation patterns. Although the human NKp46 carries both O- and N-glycosylations that are essential for its activity, the
mouse Ncr1 was predicted to have N-linked glycosylations only. Here we discovered using prediction algorithms and high-
performance liquid chromatography analysis that Ncr1 carries two putative novel O-glycosylations, one of which (Thr 225)
is conserved in NKp46. We next used surface plasmon resonance, biochemical, mutational and functional in vitro and in vivo
assays to demonstrate that the putative O-glycosylations of Ncr1 are critical for its function.
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Introduction
Nature killer (NK) cells are lymphocytes of the
innate immune system. They recognize and eliminate
virally infected cells [1–3], various malignancies [4–7],
self-cells [8, 9] and bacteria [10–12]. NK cell cytotoxi-
city is executed by various activating receptors such as
NKG2D, 2B4, NKp80 and the natural cytotoxicity
receptors (NCRs): NKp30, NKp44 and NKp46 [13].
Of the NCRs, only NKp46 has a functional mouse
Ortholog, named Ncr1 [14]. The importance of NK
cells in general, and NKp46/Ncr1 in particular was well
demonstrated, primarily via the use of Ncr1 knockout
mice, denoted Ncr1gfp/gfp [2, 4, 5, 7, 11, 12, 15–18].
However, despite years of research, the identity of the
cellular/tumor ligand/s recognized by NKp46/Ncr1 is
still obscure. In contrast, the hemagglutinin (HA)
proteins of inﬂuenza virus and Sendai as well as the HA
proteins of Newcastle [19] and Pox viruses [3] were
discovered as ligands for the activating receptors
NKp46/Ncr1 and NKp44. Sialic acids attached to
glycosylated residues of NKp44 and NKp46 were
shown to be critical for their interaction with HA [1, 18,
20]. Although very similar in structure, the human
NKp46 and the murine Ncr1 differ in their glycosyla-
tion pattern. Whereas the human NKp46 is predicted
to have two O-glycosylated residues: Thr 125 and Thr
225 and one N-glycosylated residue: Asn 216 [21], the
murine Ncr1 is predicted to have three N-glycosyla-
tions, expressed on Asn 139, Asn 216 and Asn 238 and
no O-glycosylated residues [14]. Interestingly, the
O-glycosylated residue Thr 225 was shown to be
critical for the human NKp46 activity against patho-
gens such as inﬂuenza and for the recognition of
various tumors [1]. Since the mouse Ncr1 was not
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predicted to have O-glycosylated residues, the question
is raised whether the mouse Ncr1 accurately mimics the
human NKp46 activities and whether NKp46 function
against tumors and pathogens can be studied in mice.
Here we discovered that Ncr1 expresses two,
putative previously unknown O-glycosylated residues
essential for its function, one of which, Thr 225, is
conserved.
Results
Identiﬁcation of novel O-linked glycosylated residues in
Ncr1
Ncr1 is predicted to have three N-linked glycosyla-
tions at positions N139, N216 and N238 [14]. Because
the O-glycosylations of NKp46 were shown to be
critical for its recognition of viral HA [1] and as Ncr1
also recognizes viral HA [18], we predicted that Ncr1
carries additional, yet unidentiﬁed O-glycosylations.
To identify these potential glycosylated residues, we
used the NetOGlyc 4.0 Server for mucin type O-Gal-
NAc O-glycosylation [22] and predicted the existence
of two putative O-glycosylated residues at positions
Thr 222 and Thr 225 (both located in the Ncr1 stalk
domain; Supplementary Figure S1). To investigate
whether Ncr1 indeed carries O-glycosylated residues,
we initially generated an Ncr1 Ig fusion protein com-
posed of the extracellular part of Ncr1 fused to human
IgG1. Then, we subjected the Ncr1 Ig fusion protein to
N-glycan and O-glycan release by hydrazinolysis. As
expected, the high-performance liquid chromato-
graphy (HPLC) chromatogram of the N-glycosylations
showed three prominent peaks (Figure 1a), indicating
the existence of N-linked glycosylations in the Ncr1
fusion proteins. The dextran standards are shown in
Figure 1b. As predicted (Supplementary Figure S1),
two prominent peaks that were eluted from the column
at ~ 70 and ~ 80min were clearly evident in the Ncr1 Ig
subjected to O-glycan release (Figure 1c), indicating
that Ncr1 Ig also carries previously unidentiﬁed
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Figure 1 Characterization of the Ncr1 glycosylations. (a–d) HPLC chromatogram of N- (a) and O- (c) linked glycan release from
the Ncr1 Ig fusion protein. The Ncr1 Ig fusion proteins N-linked glycans were released in solution with PNGase F before O-linked
glycan analysis. (b, d) are the dextran standards. The data are shown as ﬂuorescence arbitrary units. The HPLC chromatograms
are representatives of two independent runs. The chromatogram shown in a is identical to a ﬁgure in a different manuscript
(Glasner et al. JI 2015, in press), as it served as control in experiments pertaining to both papers, performed simultaneously.
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O-glycosylations. The dextran standards are shown in
Figure 1d. The O-glycosylation analysis was performed
following the removal of N-glycosylation by PNGase F
(see Materials and Methods).
Ncr1 isolated from primary NK cells carries O-linked
glycosylations
To demonstrate that Ncr1 expressed on primary
mouse NK cells is O-glycosylated, we initially immu-
noprecipitated the Ncr1 protein from NK cells
obtained from wild-type (WT) (Ncr1+/+) and (Ncr1
knockout Ncr1gfp/gfp) mice [2]. GAPDH levels in the cell
lysates were more or less equivalent (Figure 2a). As can
be seen in Figure 2b, Ncr1 was successfully precipitated
(detected by the anti-Ncr1 monoclonal antibody
(mAb) that we have generated, mNcr1.5). The Ncr1
knockout mice do not express the protein. Next, we
stained the precipitated proteins with lectins that pre-
ferentially bind O-linked glycosylations: Jacalin (JAC)
[23] and wheat germ agglutinin [24]. As can be seen in
Figure 2c and d, both lectins recognized the endogen-
ous mouse Ncr1 protein, suggesting that Ncr1 carries
putative O-linked glycosylations. The results were
quantiﬁed in Figure 2e–g.
Residues T222 and T225 of Ncr1 are O-glycosylated
To demonstrate that the predicted T222 and T225
residues of Ncr1 are indeed O-glycosylated, we muta-
ted each of the predicted glycosylated threonine (Thr)
residues separately to alanine (Ncr1 T222A and Ncr1
T225A) and both Thr residues together (Ncr1 T222
225A). We fused the extracellular parts of these
receptors to the Fc part of human IgG1 and produced
the corresponding fusion proteins.
It is very unlikely that mutating the O-glycosylated
residues T222 and T225 of Ncr1 would affect the
protein structure. This is because both residues are
located in the stalk domain of Ncr1. Although the
crystal structure of Ncr1 was not solved yet, the
structures of NKp46 and NKp30 were solved [25–28]
and in both cases, the stalk domains were unstructured,
indicating that the stalk is highly ﬂexible and does not
adopt a deﬁned secondary structure. Because the
structures of Ncr1 and NKp46 are very similar, com-
posing of a stalk domain and two Ig domains
(Supplementary Figure S1), it is very probable that the
stalk domain of Ncr1 that contains the O-glycosylated
residues, does not adopt a deﬁned secondary structure
either. Nevertheless, to exclude the possibility that the
mutations in the Ncr1 Thr residues disrupted somehow
the protein structure, we generated eight new anti-Ncr1
mAbs and tested whether the various WT and mutated
Ncr1 fusion proteins can be recognized by the various
mAbs. All eight mAbs recognized all WT and mutated
fusion proteins equally well (Supplementary Figure
S2), suggesting that the folding of the mutated Ncr1
fusion proteins was not disrupted.
Next, we ran the various Ncr1 Ig proteins on SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) gels
(Figure 3a shows the Coomassie staining) and per-
formed western blot assays with four lectins: Jacalin
(Figure 3b), wheat germ agglutinin (Figure 3c) and two
additional lectins, Maackia amurensis lectin II, which
preferentially binds sialic acid residues attached in an
α2,3 linkage (Figure 3d) and the Sambucus nigra lectin,
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Figure 2 Ncr1 expressed on primary NK cells carries O-linked glycosylations. (a) Western blot (WB) for GAPDH in the whole-cell
lysates of puriﬁed NK cells derived from WT and Ncr1gfp/gfp mice before imunoprecipitation. (b–d) Ncr1 protein from WT and
Ncr1gfp/gfp mice was immunoprecipitated with the mNcr1.6 mAb, blotted and stained with the mNcr1.5 mAb (b), Jacalin (JAC) (c)
and wheat germ agglutinin (WGA) (d) lectins. WB ﬁgures were adjusted for better clarity. (e–g) Ratio between the GAPDH
staining and the mNcr1.5 mAb (e) or lectins (f, g) staining (quantiﬁed by pixel intensity). Values are shown as mean± s.e.m.;
*Po0.05. The ﬁgures combine three independent experiments.
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which preferentially binds sialic acids attached to a
terminal galactose in an α2,6 linkage [29] (Figure 3e).
The WTNcr1 was well stained by all lectins, indicating
that the novel O-linked glycosylations are present in
the fusion proteins. Importantly, each of the mutated
fusion proteins was stained to a signiﬁcantly lower
degree by all lectins (Figure 3b–e, quantiﬁed in Figure
3f–i). To directly demonstrate that residues 222 and
225 carry O-linked glycosylations, we subjected each of
the WT and mutated fusion proteins to O-glycan
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release by hydrazinolysis and compared the O-linked
glycosylations proﬁles following HPLC separations.
The O-glycosylation analysis was performed following
the removal of N-glycosylations by PNGase F (see
Materials and Methods). As can be seen in Figure 3j–
m, both prominent peaks, observed in the WT Ncr1 at
~ 70 and ~ 80min (Figure 3j), were signiﬁcantly
reduced in the Ncr1 T222A Ig (Figure 3k). In the Ncr1
T225A Ig (Figure 3l), only the ~ 70 peak was reduced
and in the double mutated Ncr1 T222 225A Ig
(Figure 3m), both peaks disappeared. The dextran
standards are shown in Figure 3n. We concluded that
probably, in the WT Ncr1 there are three major
glycoforms, which occupy both T222 and T225. In the
T222A mutant there is a decrease in the ~ 80 and ~ 85
peaks and disappearance of the ~ 70 peak, which might
be explained by the loss of the T222A site. In the
T225A, the increase in the ~ 80 peak and the decrease in
the ~ 70 peak might indicate a sugar composition
change in which the occurrence of the ~ 80 peak
glycoform in position T222 is favorable.
The O-linked, but not the N-linked residues of Ncr1 are
important for its recognition and function against
various tumors
The identity of the tumor ligand/s of NKp46/Ncr1 is
still unknown. To gain insight into the molecular
properties of the NKp46/Ncr1 unknown tumor ligand
and to test whether the O- and N-glycosylations of
Ncr1 are involved in its tumor recognition, we pre-
pared an additional Ncr1 fusion protein, in which all
N-linked glycosylated residues are mutated (Ncr1
N139 216 238A Ig). Similarly to the O-glycosylations
mutants, it seems that mutating the N-glycosylated
residues of Ncr1 did not affect its folding as all eight
anti-Ncr1 mAbs recognized this fusion protein
(Supplementary Figure S2). Next, we assayed the
binding of the various mutated Ncr1 Ig proteins to
murine tumors. As can be seen in Figure 4a, the
negative control, primary mouse NK cells, were not
recognized by any of the tested fusion proteins. The
EL4 and PD1.6 mouse cell lines were recognized by
Ncr1 Ig and slightly better by the Ncr1 N139 216 238
Ig. Importantly, recognition by the O-linked mutants
of Ncr1 was markedly impaired (Figure 4a). Similar
results were obtained with various other mouse and
human tumor lines (Supplementary Figure S3A and B,
respectively). Thus, we concluded that the O-linked
residues of Ncr1 have an important role in its tumor
ligand recognition.
To further conﬁrm the above results, we also per-
formed competition assays. In these experiments, we
incubated EL4 cells with 5 μg (saturating concentra-
tion) of each of the various WT and mutated Ncr1
fusion proteins. Next, we used a biotinilated Ncr1 Ig to
stain the blocked and unblocked EL4 cells. Before
these assays, we conﬁrmed that the binding of the
biotinilated and non-biotinilated Ncr1 Ig fusion pro-
teins is identical (data not shown). As can be seen in
Figure 4b, preincubation of EL4 cells with the WT
Ncr1 Ig or with the Ncr1 N139 216 238A Ig mutant
blocked the biotinilated Ncr1 Ig binding. In contrast,
little or no blocking was observed with each of the
O-linked mutated Ncr1 Ig fusion proteins (Figure 4b).
To test whether the newly identiﬁed O-linked Thr
residues of Ncr1 are important for its function against
tumors, we used a cell-based reporter assay in which we
cloned the extracellular parts of the mouse Ncr1 and its
various N- and O-sugar mutants, fused them to the
mouse zeta chain and expressed them in mouse BW
cells. In the BW reporter system, the triggering of Ncr1
leads to IL2 secretion, thus reporting for the functional
interaction of Ncr1 with its ligand.
All mutated O-glycosylated proteins were expressed
on the cell surface (Figure 4c), further indicating that
the mutations did not affect the protein structure. In
contrast, the expression of the triple N-mutant (Ncr1
N139 216 238A) was unstable. It appeared on the cell
surface in delay and its expression was lost from the cell
surface within a week.
Figure 3 Thr 222 and Thr 225 are glycosylated. (a) Coomassie staining of the various Ncr1 fusion proteins (5 μg) run on 10% SDS-PAGE
gel under reducing conditions. (b–e) Western blot (WB) performed on the various Ncr1 fusion proteins shown in a. Staining was
performed with Jacalin (JAC) (b), wheat germ agglutinin (WGA) (c), Maackia amurensis lectin II (MAL) (d) or Sambucus nigra (SNA) (e)
lectins. WB and Coomassie ﬁgures were adjusted for better clarity. The ﬁgures combine at least three independent experiments. (f–i)
Ratio between the Coomassie staining and the WB staining (quantiﬁed by pixel intensity) of the various lectins. Values are shown as
mean± s.e.m.; *Po0.05. (j–n) HPLC chromatogram of O-linked glycan release from the Ncr1 Ig (j), Ncr1 T222A Ig (k), Ncr1 T225A Ig (l)
and Ncr1 T222 225A Ig (m) fusion proteins and dextran standards (n). The various Ncr1 Ig fusion proteins N-linked glycans were
released in solution with PNGase F before O-linked glycan analysis. The data are shown as ﬂuorescence arbitrary units. The
chromatogram shown in j is identical to the one shown in Figure 1c albeit presented in a different time scale. The HPLC chromatograms
are representatives of two independent runs.
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Figure 4 The O-linked glycosylations of Ncr1 are important for its function against various tumors. (a) FACS staining of murine cell
lines and primary NK cells, as indicated. Staining was performed with various Ncr1 Ig fusion proteins (listed in the bottom of the
ﬁgure, black line histograms). The gray ﬁlled histograms are the backgrounds secondary mAb staining. The median ﬂuorescent
intensities (MFIs) of the fusion proteins staining are indicated. (b) FACS staining of EL4 cells that were untreated or blocked with
the indicated fusion proteins. The cells were then stained with biotinilated Ncr1 Ig. The gray ﬁlled histograms are the backgrounds
secondary mAb staining of the unblocked EL4 cells. The blocked EL4 cells background was identical to the unblocked and is not
shown in the ﬁgure. The MFIs of the fusion proteins staining are indicated. (c) FACS staining of BW transfectants expressing the
various Ncr1 proteins, as indicated. Staining was performed with anti-mNcr1.15 mAb (black line histograms). The gray ﬁlled
histograms represent the background staining with the secondary anti-mouse antibody. MFIs of the anti-Ncr1 mAb staining are
indicated. (d, e) IL2 secretion from the various BW transfectants presented in (c) following 48-h incubation with murine EL4 (d)
and PD1.6 (e) cells. Values are shown as mean ± s.e.m. *Po0.05. The entire ﬁgure represents data collected from three
independent experiments of each assay.
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To study the causes responsible for the unstable
properties of the triple N-mutant Ncr1 (Ncr1 N139 216
238A), we expressed the full-length WT and mutated
Ncr1 proteins in HEK 293T cells. We observed that
while the WT and O-linked mutants were well expres-
sed, the Ncr1 N139 216 238A appeared on the cells
surface in delay and its expression was unstable due to
endoplasmic reticulam arrest (data not shown).
Because the expression of Ncr1 N139 216 238A zeta
was unstable, experiments had to be performed quickly
and be completed within a week. Incubation of WT
Ncr1, as well as the Ncr1 N139 216 238A zeta mutant
with EL4 and PD1.6 resulted in comparable levels of
IL2 secretion (Figure 4d and e, respectively). In con-
trast, signiﬁcantly less IL2 was secreted on incubation
of EL4 or PD1.6 with all of the O-glycosylated mutants
(Figure 4d and e). Thus, we concluded that the novel
O-linked glycosylations of Ncr1 are important for its
recognition of—and activation by—tumor ligands.
The novel O-linked glycosylations of Ncr1 are essential
for inﬂuenza recognition
To further corroborate the above results, we grew
the Ncr1 Ig protein in the absence or presence of
tunicamycin (TM), which blocks N-linked glycosyla-
tions in eukaryotic cells and ran the Ncr1 fusion pro-
teins on SDS-PAGE gel. As can be seen in Figure 5a,
the TM-treated Ncr1 Ig demonstrated a two-band
pattern, which was different from the untreated Ncr1
Ig, suggesting that the TM treatment was effective. We
next tested the binding of the TM-treated and
untreated fusion proteins to the PD1.6 cell line and
observed a slight increase in the binding of TM-treated
Ncr1 Ig (Figure 5b). Similarly to what we observed
with the Ncr1 N139 216 238A Ig (Figure 4a and
Supplementary Figure S3). Similar results were
obtained with other tumors (data not shown).
We have previously demonstrated that the Ncr1
glycosylations are important for its interaction with
viral HA, although the identity of the glycosylated
residues remained unknown [18]. Thus, to test whether
the TM-treated Ncr1 Ig protein would still bind to
inﬂuenza, we incubated EL4 cells with PR8 inﬂuenza
(Figure 5c) and tested the staining with both Ncr1
proteins (TM treated or not). Signiﬁcant elevation of
staining by both proteins was detected (Figure 5d).
Collectively, these data suggest that the N-glycosyla-
tions of Ncr1 are not important for its binding to
inﬂuenza and tumor cells.
We next investigated whether the newly identiﬁed
O-glycosylated residues of Ncr1 are important for its
HA recognition. EL4 cells express high levels of the
unknown Ncr1 tumor ligand (see ﬁgures above).
Therefore, to minimize the background staining of
Ncr1 Ig to its unknown tumor ligand/s, we used a low
fusion protein concentration in which almost no Ncr1
Ig staining was observed (Figure 5e). Interestingly,
although increased binding of the WT Ncr1 Ig and
Ncr1 N139 216 238A Ig was observed to the PR8-
treated cells (Figure 5e), the interaction of each of the
O-linked mutated Ncr1 Ig fusion proteins with the
PR8-EL4 cells was signiﬁcantly less pronounced.
To further conﬁrm the above results, we incubated
EL4 cells with PR8 inﬂuenza and then preincubated the
cells with 5 μg of each of the various WT and mutated
Ncr1 Ig fusion proteins. Next, we stained the cells with
the biotinilated Ncr1 Ig fusion protein. Pretreatment of
PR8-EL4 cells with the WT Ncr1 Ig or Ncr1 N139 216
238A Ig blocked the biotinilated Ncr1 Ig binding.
Pretreatment with each of the O-linked mutated Ncr1
Ig fusion proteins had little or no effect (Figure 5f).
We also tested the functionality of the O-glycosy-
lated residues of Ncr1 against inﬂuenza by using the
BW reporter system. Signiﬁcantly, more IL2 was pro-
duced when the Ncr1 zeta and Ncr1 N139 216 238A
zeta BW cells were incubated with EL4 PR8 inﬂuenza
compared with the BW cells expressing the O-linked
Ncr1 mutants (Figure 5g).
The novel O-linked glycosylations of Ncr1 are important
for its direct interaction with viral HA in vitro and in vivo
To demonstrate that Ncr1 directly interacts with
viral HA via its O-glycosylated residues, we cloned the
extracellular part of the HA protein of PR8 inﬂuenza
and fused it to human IgG1. We next ran the WT Ncr1
protein and the O-glycosylated mutants of Ncr1 on
SDS-PAGE gel (Figure 6a) and WB them with HA Ig.
A direct HA Ig binding was detected to Ncr1 Ig. All
O-mutants of Ncr1 were less recognized (Figure 6b,
quantiﬁed in Figure 6c).
We also performed surface plasmon resonance
experiments using WTNcr1 Ig and Ncr1 T222 225A Ig
immobilized on a CM5 sensor chip and the recombi-
nant HA as analyte at a series of concentrations.
Immobilizing the HA to the chip and passing Ncr1 Ig
and Ncr1 T222 225A Ig as analytes was also tried,
however conjugated HA protein gave no response with
analyte Ncr1 Ig proteins, presumably because HA
multimers did not stay intact on immobilization. We
assessed binding afﬁnities using relative response from
a region of the sensogram that is closest to the steady
state. Saturating conditions were not reached even with
high concentrations of HA, therefore, the steady-state-
binding model could not be applied. Dissociation of
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HA was also excessively slow to be measured, pre-
cluding application of the kinetic model. Thus, binding
levels for a given concentration were compared.
Although quantitative evaluation of the binding afﬁ-
nity constants between HA and Ncr1 Ig and its mutant
was not possible, a qualitative comparison could be
made on the basis of the response levels as a function of
HA (analyte) concentration. As can be seen in
Figure 6d, the binding of Ncr1 T222 225A Ig to HA
was signiﬁcantly impaired, compared with the WT
Ncr1 Ig. Thus, we concluded that the newly identiﬁed
O-linked glycosylations of Ncr1 are critical for the
direct Ncr1 recognition of HA.
To test the function of the O-linked glycosylated
residues of Ncr1 in vivo, we infected C57BL/6 mice with
PR8 inﬂuenza virus. The virus was either untreated or
preincubated with the WT and the sugar mutated Ncr1
Ig fusion proteins. We hypothesized that if the fusion
proteins interact with the HA protein, we would expect
the infection to be reduced because the HA protein is
important for virus entry into the cells. As can be seen
in Figure 6e, mice that were infected with inﬂuenza
virus preincubated with fusion proteins that are able to
bind HA, that is, WT Ncr1 Ig and Ncr1 N139 216 238
Ig, lost signiﬁcantly less weight than mice that were
infected with inﬂuenza virus preincubated with the
O-glycosylated mutated fusion proteins.
Collectively, we demonstrate that the newly identi-
ﬁed O-glycosylated residues Thr 222 and Thr 225 of
Ncr1 are essential for its activity, in vitro and in vivo.
The novel O-linked glycosylations of Ncr1 are important
for its function in primary NK cells
We demonstrated above using fusion proteins,
HPLC and reporter assays that Ncr1 carries O-glyco-
sylations essential for its function. O-glycosylations
might vary between different cells and thus ideally it
would be important to demonstrate that the newly
identiﬁed putative O-glycosylations function in pri-
mary mouse NK cells. We initially tried expressing the
WT Ncr1 and the mutated Ncr1 proteins in the mouse
NK cells derived from Ncr1 knockout mice (Ncr1gfp/gfp)
[2]. Despite our best efforts and although we employed
several methods of gene insertion (including retro-
and lentiviral infection), we were unsuccessful.
Importantly, we were able to express the Ncr1 and
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mutated Ncr1 in IL2-activated human primary NK
cells, using lentiviral infection (see detailed protocol in
the Materials and Methods section). The expression
levels of Ncr1 mutated at the O-linked residues and of
WT Ncr1 were similar (Figure 7a). In agreement with
our above results, the Ncr1 protein mutated in all
N-glycosylated positions could not be expressed in IL2-
activated primary human NK cells.
As human NK cells express receptors that bind and
are activated by inﬂuenza virus HA (NKp44 and
NKp46) [1, 16, 17, 20], we had to block these interac-
tions using blocking mAbs. Next, in order to determine
whether the O-glycosylated residues of Ncr1 are
essential for its inﬂuenza virus recognition, we
expressed the WT Ncr1 or Ncr1 T222 225A proteins in
primary bulk IL2-activated human NK cells, blocked
NKp44 and NKp46 with anti-NKp44- and anti-
NKp46-blocking mAbs and incubated the Ncr1 and
Ncr1 T222 225A transduced NK cells with PR8-
infected Jeg3 cells. We used Jeg3 cells here because
these are human cells that do not express any known
ligands for NK-activating receptors and are therefore
minimally killed in the absence of inﬂuenza. NK cell
cytotoxicity was assayed by CD107a degranulation
assays. Importantly, we observed signiﬁcant degranu-
lation with the WT Ncr1-expressing human NK cells
and practically no degranulation with the T222 225A
mutant (Figure 7b).
Discussion
Human NKp46 and murine Ncr1 share many
structural similarities. However, although NKp46 is
predicted to have two O-linked glycosylations and one
N-linked glycosylation, the murine Ncr1 was predicted
to have, only N-linked glycosylations at positions Asn
139, Asn 216 and Asn 238 [14]. Using the NetOGlyc
4.0 Server for mucin type O-GalNAc O-glycosylation
[22], combined with HPLC analysis and mutants gen-
eration, we identiﬁed two putative previously unchar-
acterized Thr residues (Thr 222 and Thr 225) carrying
O-linked glycosylations in Ncr1, which are essential for
its function.
Ideally, it would be interesting to identify the
exact glycan residues of Ncr1 isolated from mouse cells
by mass spectrometry-based methods. However,
these experiments, using the technology at hand,
would require sacriﬁcing thousands of mice. Instead,
we immunoprecipitated the endogenous Ncr1 protein
from primary mouse NK cells and demonstrated that
Ncr1 carries putative O-glycosylations. In addition, we
expressed the Ncr1 and O-glycosylated mutant in pri-
mary human NK cells and demonstrated that the
newly identiﬁed O-glycosylated residues of Ncr1 are
essential for inﬂuenza recognition.
Inﬂuenza virus infection poses a severe health threat
and a substantial economic burden to modern society
[30, 31]. The several inﬂuenza virus pandemics out-
breaks that had occurred in the last two centuries, stress
the importance of studying and understanding the
inﬂuenza virus activity and its interactions with the
immune system.
In 2001, the inﬂuenza virus and Sendai virus’ HAs
were discovered as ligands for the activating receptors
NKp46 and NKp44 [20]. Sialic acids attached to
O-glycosylated residues of NKp46 were shown to be
critical for their interaction with HA [1, 20].
The sialic acid-based mechanism of NKp46 recog-
nition of infected cells was probably developed by the
NK cells to ensure the recognition of various inﬂuenza
viruses. The inﬂuenza virus HA undergoes rapid and
extensive changes to avoid detection by the immune
system [32] and indeed around 10 000 different viral
HA sequences exist in the data bank. However, the
ability of viral HA to bind sialic acids is conserved [33].
NK cells utilize this property to kill the infected cells
via the interaction between viral HA and the sialic
acids residues expressed, as we show here, by O-gly-
cosylated residues on Ncr1.
We demonstrated here that the newly identiﬁed
putative O-glycosylated residues of Ncr1 are essential for
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its HA recognition. Remarkably, although the human
NKp46 and mouse Ncr1 differ in their glycosylations,
still residue T225 is conserved in humans and mice.
Interestingly, however, in Ncr1, an additional residue
(T222) is important for Ncr1 recognition and function.
We think that the proximity between the 222 and 225
glycosylations probably hints at some redundancy. It is
common for a change in one glycosylation site to affect
the glycosylation at other positions in the protein.
Indeed, we demonstrated that the disruption of oneNcr1
Thr residue or both residues together produced more or
less the same effects. With this regard, the T222 and
T225 positions of Ncr1 are located in the stalk region,
where two of the protein’s N-linked glycosylations are
also located. Thus, it might be that the N-glycosylations
of these proximal residues are also affected. However,
even if this is the case, it has no role in Ncr1 function, as
mutating all N-linked glycosylated residues of Ncr1 did
not affect its recognition, binding or function.
Mutating each of the newly identiﬁed putative
O-glycosylated residues and of both residues together
impaired not only the Ncr1 recognition of HA but also
the recognition of various mouse and human tumors.
As the NKp46/Ncr1 cellular ligands are unknown, it is
quite difﬁcult to directly test these interactions.
Nevertheless, our results suggest that the putative
O-glycosylations of Ncr1 are involved in the recogni-
tion of many mouse and human tumors. NKp46 and
Ncr1 are also similar in that sense as the O-glycosyla-
tions of NKp46 were also shown to be important for its
tumor recognition [1].
As both O-glycosylated putative positions of Ncr1
reside in the unstructured stalk domain, it is very
unlikely that mutating these residues disrupted the
Ncr1 structure. To further exclude this unlikely possi-
bility, we produced eight new anti-Ncr1 mAbs and
demonstrated that all recognized the WT and mutated
Ncr1 proteins. In addition, when expressed in BW cells
the WT and O-linked mutated Ncr1 proteins were
equally well expressed on the cell surface and were
equally recognized by anti-Ncr1 mAbs. Furthermore,
equal expression levels of the WT and the O-glycosy-
lation mutants were detected on the surface of primary
human NK cells.
Thus, we do not think that mutating the O-gluco-
sylated residues of Ncr1 had an effect on the Ncr1
protein structure.
Interestingly, although unstructured, the stalk
domains have an important role in the recognition of
several targets by NCRs members. In NKp44 and
NKp46, sialic acids moieties in the stalk domain
interact with viral HAs [1, 18, 19, 20]. NKp30 was also
shown to interact with its targets in a stalk domain-
glycosylations-mediated manner [34].
The Ncr1 was cloned almost two decade ago [14]
and since then it was demonstrated to be critical in
many pathological conditions [1–8, 10, 11, 16–20, 35].
However, the identity of the cellular ligand/s recog-
nized by Ncr1 is still unknown. We demonstrate here
that putative O-glycosylations of Ncr1 are important
for all interactions. It is thus possible that similarly to
HAs (the viral ligands of Ncr1), the tumor ligands or
co-ligands recognized by Ncr1 might be lectins.
Materials and Methods
Generation of Ig fusion proteins, cell transfectants and TM
treatment
Fusion proteins were generated in HEK293T cells, as
previously described [20]. In short, the extracellular parts of
Ncr1, the HA of PR8 inﬂuenza virus, NKp44 and NKp46 were
ampliﬁed by PCR and cloned in frame with human IgG1.
Mutations in the Ncr1 protein were generated by PCR. For
the generation of the lentiviral vectors, the Ncr1 proteins were
cloned and the various mutations were generated by PCR. TM
was used at 5 μg ml when relevant. For the generation of the BW
reporter cells, the extracellular parts of the Ncr1 and various
Ncr1 mutants described above were fused to the mouse CD3
zeta chain. The various Ncr1 zeta constructs were expressed in a
lentiviral vector and transduced in BW cells. The BW assays
were performed as previously described [20]. In brief, BW cells
expressing the various Ncr1 receptors fused to the mouse zeta
chain were incubated at a ratio of 1:1 with target cells at 37 °C
and 5% CO2. Following 48 h of incubation, the supernatants
were collected, and IL2 levels were measured using standard
enzyme-linked immunosorbent assay.
Generation of anti-mNcr1 mAbs and blocking of Ig fusion
proteins binding
The various anti-mNcr1 mAbs used in this study were
generated by immunizing Ncr1gfp/gfpBalb/c mice [2, 18] with the
Ncr1 Ig fusion protein that we have generated. Biotynilation of
Ncr1 Ig was performed using EZ-Link Sulfo-NHS-SS-Biotin
(Thermo Scientiﬁc, Rockford, IL, USA) according to the
manufacturer’s instruction. For blocking the staining by the
biotynilated Ncr1 Ig, each of the WT and mutated fusion pro-
teins used in this study were incubated with the untreated or
PR8-treated EL4 cells for 2 h. Next, the biotinylated Ncr1 Ig
was added to the cells incubated with the various fusion proteins,
left on ice for an additional hour and then the cells were washed
and stained with a streptavidin-conjugated secondary mAb.
Immunoprecipitation and western blotting
Immunoprecipitation of Ncr1 was performed following
standard immunoprecipitation protocol, using agarose A/G
beads and the anti-Ncr1 mNcr1.6 mAb. For western blotting,
the precipitated proteins were run on a 10% SDS-PAGE gel,
transferred and stained with anti-mNcr1. For the western blot-
ting with lectins, the various fusion proteins (5 μg) were run on
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10% SDS-PAGE gel, transferred to a nitrocellulose membrane
(Tamar, Mevaseret Zion, Israel) and blotted with biotin-
conjugated lectins (Jacalin, wheat germ agglutinin, Maackia
amurensis lectin II and SNA, all from Vector labs, Burlingame,
CA, USA) or with biotin-conjugated HA Ig. The staining was
visualized using a streptavidin HRP secondary reagent and EZ
ECL substrate (Biological Industries, Beit-Haemek, Israel).
Preparation of the fusion proteins for sugar content
analysis and HPLC
For O-glycosylation analysis, 250 μg puriﬁed Ncr1 Ig and
Ncr1 T222 225A Ig were reduced with 10mM dithiothreitol for
10 min at 70 °C, before alkylation with 55 mM iodoacetamide for
30min at room temperature (protected from light). The Ncr1 Ig
Ncr1 T222A Ig, Ncr1 T225a Ig and Ncr1 T222 225A Ig
N-linked glycans were released in solution with PNGase F.
For O-glycan release, the de-N-glycosylated glycoproteins
were lyophilized before hydrazinolysis. Samples were incubated
with anhydrous hydrazine for 6 h at 60 °C to release the O-linked
glycan (glycan hydrazinolysis kit, catalog no. GK50202; Glyco/
Prozyme (ProZyme, Inc., Hayward, CA, USA)). Excess hydra-
zine was removed by evaporation, and the glycans were re-N-
acetylated with acetic anhydride in a saturated solution of sodium
bicarbonate. Peptides were removed by descending paper chro-
matography on prewashed Whatmann 3-mm chromatography
paper in butanol/ethanol/water (8:2:1 (vol/vol)) for 70 h. Glycans
were recovered from the paper (1–3 cm from origin) by washing
with 1.5ml of water. A rotary evaporator was used to concentrate
the samples, which were then stored at 20 °C before labeling with
2AB (2-aminobenzamide).
Exoglycosidase digestion of the sialic acid was performed on
the released, 2AB-labeled glycan solution containing Arthro-
bacter ureafaciens sialidase (sialidase A, cleaves both 2,3 and 2,6
sialic acid residues; ABS, Glyco/Prozyme). Normal phase
HPLC was performed with the low-salt buffer system using a
4.6- by 250-mm GlycoSep N column (OGS; Waters, Milford,
MA, USA). The solvents used were buffer B (50 mM ammonium
formate, pH 4.4) and buffer C (acetonitrile). The glycans were
eluted by linear gradient with buffer B, with initial conditions of
20% buffer B at a ﬂow rate of 0.4 ml min. The concentration of
buffer B was changed from 35 to 53% over 132 min and then
from 53 to 100% over the next 3 min, with a constant ﬂow rate.
The column was washed with 100% buffer B for 5 min at a ﬂow
rate of 1 ml min before re-equilibration in the initial solvent
system. Fluorescence was measured at 420 nmwith an excitation
of 330 nm (with 16-nm bandwidths).
Surface plasmon resonance
Surface plasmon resonance assays were performed using Bia-
core T100 biosensor (GE Healthcare, Uppsala, Sweden). WT and
mutated Ncr1 were dissolved in Biacore immobilization buffer
(10mM sodium acetate, pH 4.0) to 30 nM and then coupled to
CM5 Series S chip (GE Healthcare) using manufacturer-
recommended amine-coupling protocol to a level of 500RU.
Recombinant H1 HA wth His Tag form Inﬂuenza A/Brisbane/
59/2007 H1N1 56 FR-69 (IRR, CDC) was dissolved in the HBS-
EP+ buffer (10mM HEPES pH 7.3, 150mM NaCl, 3 mM EDTA
pH8 and 0.05% Tween20) and was injected in concentrations:
0.78, 1.56, 3.12, 6.25, 12.5, 25, 50 and 100 nMusing 50 μl min ﬂow
rate; 100 s. Dissociation was measured for 120 s. The surface was
regenerated by a single 30-s pulse of 10mM NaOH.
Mice and inﬂuenza virus
All experiments were performed using 4–5-week-old C57BL/
6 mice. The generation of the Ncr1gfp/gfp mouse was previously
described [2]. All the experiments were performed in a speciﬁc
pathogen-free unit of the Hebrew University Medical School
(Ein-Kerem, Jerusalem) in accordance with the guidelines of the
ethics committee (MD-12-13471-5). Propagation of the human
inﬂuenza virus A/Puerto Rico/8/34 H1N1 (PR8) was performed
as previously described [18].
Expression of Ncr1 in primary human NK cells and
CD107a assay
The full-length Ncr1 and T222 225A Ncr1 were each cloned
into a lentiviral vector (pHAGE-DsRED(− )-eGFP(+), which
also contains green ﬂuorescent protein (GFP) [36]). 293T cells
(3.5 ×105 per well) were seeded in 15 six-well plates in 2 ml
DMEM a day prior transfection. The WT or O-glycosylated
mutant of Ncr1 vectors, a plasmid encoding the lentiviral Gag/
Pol, and a plasmid encoding the VSV-G were transfected in the
293T cells using Mirus reagent (TransIT-LT1, Mirus, Madison,
WI, USA), according to the manufacturer instructions. Forty-
eight hours following transfection, 180 ml of medium containing
the lenti viruses was collected. The medium was then ﬁltered
using 0.2-μm ﬁlters and the lenti viruses were used to infect
primary IL2-activated bulk human NK cells. The human NK
cells used in this study were obtained from the blood of healthy
volunteers. The institutional Helsinki committee of Hadassah
approved the study (Helsinki number 0030-12-HMO). All sub-
jects provided a written informed consent. Peripheral blood
mononuclear cells (PBMCs) were puriﬁed from heparinized
blood by the centrifugation on LymphoprepTM (StemCells
Technologies, Vancouver, BC, Canada). NK cells were isolated
using the EasySepTM humanNK cell enrichment kit (StemCells
Technologies). Activated NK cells were generated by culturing
isolated NK cells together with irradiated feeder cells (2.5 × 104
allogeneic PBMCs from two donors and 5×103 8866 B cells in
each well) and 20 μg ml PHA (Roche, Rehovot, Israel). Both
PBMCs and 8866 B cells were irradiated in 6000 rad before
seeding in 96-well U-bottom plates. The cultures were main-
tained in DMEM:F-12 Nutrient Mix (Sigma Aldrich, Rehovot,
Israel; 70:30), 10% human serum (Sigma Aldrich), 2 mM
glutamine (Biological Industries; BI, Beit-Haemek, Israel), 1 mM
sodium pyruvate (BI), 1 × nonessential amino acids (BI), 100
Uml penicillin (BI), 0.1 mgml streptomycin (BI) and 500 Uml
rhIL-2 (Peprotech, Rehovot, Israel). NK cells were stained with
anti-CD56 phycoerythrin (BD Biosciences, San Jose, CA, USA)
and anti-CD3 allophycocyanin (Biolegend, San Diego, CA,
USA) to conﬁrm NK purity after isolation and following
activation. A week later, irradiated feeder cells (2.5 × 104
allogeneic PBMC from two donors and 5× 103 8866 B cells in
each well) were added.
Two hundred NK cells were seeded per well of each of 18
96-well plates in 100 μl of the ﬁltered virus-containing DMEM
medium supplemented with 2mM glutamine (BI), 1mM sodium
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pyruvate (BI), 1× nonessential amino acids (BI), 100Uml
penicillin (BI) and 0.1mgml streptomycin (BI). Then, the plates
were centrifuged for 2 h at 28 °C, 648g. On the next day (24 h
following infection) 100 μl were added of the DMEM:F-12
Nutrient Mix (70:30), 10% human serum (Sigma Aldrich), 2 mM
glutamine (Biological industries; BI), 1 mM sodium pyruvate (BI),
1× nonessential amino acids (BI), 100Uml penicillin (BI), 0.1
mgml streptomycin (BI) and 500Uml rhIL-2 (Peprotech). On the
next day (48 h following infection), the cells were collected and
sorted using SH800Z Cell Sorter Sony Biotechnology Inc.
(Weybridge, Surrey, UK) based on GFP expression. We then
veriﬁed that Ncr1 is expressed using an allophycocyanin-
conjugated anti-mNKp46/Ncr1 (29A1.4 (Rat IgG2a, κ;
Biolegend) mAb.
For CD107a degranulation assays of the Ncr1-expressing
human NK cells, 1000 NK cells per well were ﬁrst pre-blocked
with 0.2 μg of each of the blocking mAbs anti-NKp44 (clone
p44-8 cat #325104) and anti-NKp46 (clone 9E2 cat #331904;
Bioledgend). Then, the transfected NK cells were incubated with
PR8-treated Jeg3 cells in a ratio of 1:1 in the presence of 0.1 μg
allophycocyanin-conjugated CD107a mAb (Biotest, Ness
Ziona, Israel) for 2 h at 37 °C. CD107a levels on the NK cells
were determined by ﬂow cytometry.
Statistical analysis
Analysis of variance was used to identify signiﬁcant group
differences.
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